Phase 2 N=344 Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.
Influenza
Primary: Time to Alleviation of Symptoms (Kaplan-Meier Estimate) — 136.2; 114.1; 117.4 Hours — p=0.377
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=124 A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults
Influenza A
Primary: Percentage of Participants With Adverse Events (AEs) — 30.2; 39.0; 30.0 percentage of participants
Phase 2 N=326 High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Influenza · Avian Influenza · Severe Influenza
Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42
Phase 2 N=150 Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A
Influenza
Primary: Assess the Safety and Tolerability of a Single IV Dose of VIS410 in Participants With Uncomplicated Influenza Infection — 57.1; 34.7; 45.9; 26.0 percentage of participants
Phase 2 N=405 A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza
Acute, Uncomplicated Human Influenza
Primary: Time to Alleviation of Symptoms (Kaplan-Meier Estimate) — 106.9; 91.1 hours — p=0.222
Phase 3 N=624 Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
Influenza
Primary: Time to Resolution of All Clinical Symptoms of Influenza as Reported by the Subjects — 109.1; 116.7; 95.5 Hours
N/A N=558 Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
Influenza, Human
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs at Day 3 -- Team Collected Samples — 99; 131 Participants…
Phase 2 N=126 A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza
Influenza
Primary: Number of Participants With Any Solicited Influenza Symptoms From Day 1 Through Day 10 — 32; 31; 31; 31 Participants
Phase 2 N=630 Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
Influenza
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs — 40; 50 percentage of participants analyzed — p=0.046
Phase 3 N=1,030 A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza
Influenza
Primary: Time From First Dose to Symptom Response — 155.1; 153.9 hours — p=0.3765
N/A N=4,561 Influenza Resistance Information Study
Influenza
Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants
Phase 3 N=37 A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal Influenza
Influenza
Primary: Percentage of Participants Excreting Resistant Virus — 26.3; 35.3 percentage of participants — p=0.825
Phase 4 N=58 ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir
Influenza
Primary: Mean Symptom Severity Score During the 2015-2016 Influenza Season for Symptom Domains as Assessed Using the Influenza-Patient Reported Outcome (FLU-PRO™) Questionnaire…
Phase 2 N=120 Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections
Acute Respiratory Viral Infections · Influenza
Primary: Time to Sustained Improvement in Clinical Symptoms Based on Modified Jackson Scale for ARVI — 57.38; 67.75; 69.64 hours — p=0.3541
Phase 2 N=137 Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza
Influenza
Primary: Time to Clinical Stability (Kaplan-Meier Estimate) — 23.7; 37.0; 28.1 hours — p=0.306
Phase 2 N=91 Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model
H1N1 Influenza Healthy Volunteers
Primary: Area Under the Curve (AUC) of Viral Shedding — 48.56; 25.53 ViralLoad(log(copies/ml))per time(hours) — p=0.31
Phase 3 N=64 Zanamivir Versus Trivalent Split Virus Influenza Vaccine
Influenza
Primary: Number of Laboratory Confirmed Influenza Infections — 2; 1 infections — p=0.25
Phase 2 N=65 Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A
Influenza A H3N2 · Influenza A H1N1
Primary: Frequency Counts and Percentage of Subjects With Adverse Events — 6; 6; 1; 3 Participants
Phase 3 N=74 Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
Influenza
Primary: Safety and Tolerability, as Measured by the Number of Adverse Events. — 17; 9; 1; 5 Participants
Phase 2 N=87 Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza
Influenza
Primary: Oseltamivir Carboxylate AUC12 (Area Under the Curve). — 6; 1; 3; 0 participants
Phase 3 N=1,436 A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Influenza
Primary: Time to Alleviation of Symptoms in Participants Randomized to Baloxavir or Placebo — 53.7; 80.2 hours — p=<0.0001
Phase 1 N=60 Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain
Influenza
Primary: Number and Percentage of Participants With Symptomatic Influenza Virus Infection After Challenge. — 4; 5; 28; 0 Participants
Phase 1 N=27 Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants
Influenza Type A · Influenza Type B · Influenza
Primary: Number of Participants Having Adverse Events — 0; 1; 1; 1 Participants
N/A N=411 Evaluation of Moderate to Severe Influenza Outcomes in Children
Influenza · Otitis Media · Lower Resp Tract Infection
Primary: Hospitalization — 26; 2 Participants
N/A N=193 Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza
Influenza
Primary: Duration of Influenza Illness — 4; 4 days
Phase 3 N=215 A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
Influenza, Human
Primary: Percentage of Participants With Adverse Events — 40.0; 47.3; 25.7; 29.1 percentage of participants
Phase 4 N=1,107 Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Influenza · Pneumonia
Primary: Number of Participants With Clinical Failure (Failure to Reach Clinical Stability) — 6; 2 Participants — p=.460
Phase 1 N=60 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)
Influenza, Human
Primary: Number of Participants With Immediate Adverse Events — 0; 0 participants
Phase 3 N=118 A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
Influenza
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events(SAEs, AEs Leading to Withdrawal, and Death — 1; 1; 3; 24 Partipants
Phase 2 N=48 Influenza A 2009 H1N1 Challenge Study in Healthy Adults
Influenza
Primary: Percent MMID — 0; 0; 20; 47 percentage of participants